Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 105Carcinoma, Hepatocellular 34Gastrointestinal Stromal Tumors 17Colonic Neoplasms 14Rectal Neoplasms 12Neoplasm Metastasis 12Liver Neoplasms 8Stomach Neoplasms 5Cholangiocarcinoma 5Pancreatic Neoplasms 4Esophageal Neoplasms 4Sarcoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Colorectal Cancer Metastatic 3Carcinoma, Renal Cell 3Advanced Colorectal Cancer 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neoplasms 2Mesothelioma, Malignant 2Melanoma 2Lung Neoplasms 2Glioblastoma 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Fatigue 2Esophageal Squamous Cell Carcinoma 2Colorectal Cancer Liver Metastases 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2

Interventions

regorafenib 1napabucasin 1Videotape Recording 1Patient Care Planning 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Gastrointestinal Cancer × regorafenib × Gastrointestinal × Clear all
NCT02024607 2023-11-15

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Sumitomo Pharma America, Inc.

Phase 1/2 Completed
495 enrolled 18 charts
Gastrointestinal

Advanced Gastrointestinal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡